ANIP
ANI Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
73.16
close · 2026-10-29
value
67
cheaper than peers67
quality
74
stronger fundamentals74
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 7.22× | 77 |
| price to sales | 1.93× | 61 |
| EV to EBITDA | 10.42× | 57 |
| price to book | 2.63× | 56 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 20.5% | 77 |
| return on equity | 18.3% | 72 |
| operating margin | 16.3% | 71 |
| debt to equity | 112.1% | 33 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $140.3M |
| employees | 970 |
| first trade | 2000-05-05 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 3.32 | -1.04 | 0.85 | -3.05 |
| free cash flow | $150.9M | $47.1M | $100.4M | -$47.7M |
| net income | $78.3M | -$18.5M | $18.8M | -$47.9M |
| revenue | $883.4M | $614.4M | $486.8M | $316.4M |
| unusual items | $32.7M | -$2.8M | -$2.6M | -$9.5M |